Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 18/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26497736 | 0.91 | BACE1 (0.41) | RIPK1 | |
| SCHEMBL26493262 | 0.87 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL26497603 | 0.79 | RIPK1 (0.39) | RIPK1 | |
| SCHEMBL21531311 | 0.78 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL21531314 | 0.78 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL25587241 | 0.76 | GRM5 (0.45) | RIPK1 | |
| SCHEMBL31656001 | 0.73 | SRD5A1 (0.40) | RIPK1 | |
| SCHEMBL15964555 | 0.73 | SRD5A1 (0.40) | RIPK1 | |
| SCHEMBL15964550 | 0.73 | AADAT (0.50) | — | |
| SCHEMBL15964551 | 0.73 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210070735-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| WO-2021046382-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070735-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885MAP3K14 205/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885MAP3K14 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.